Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)
NCT03064490
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
35
Enrollment
OTHER
Sponsor class
Conditions
Locally Advanced Esophageal and Gastric Cancers (EGC)
Interventions
DRUG:
Pembrolizumab
Sponsor
Duke University